News articles about Ultralife (NASDAQ:ULBI) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ultralife earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned headlines about the technology company an impact score of 45.6018239351606 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Ultralife (NASDAQ ULBI) opened at $6.60 on Wednesday. Ultralife has a 52 week low of $4.70 and a 52 week high of $7.90. The stock has a market cap of $96.89, a price-to-earnings ratio of 17.22 and a beta of -0.17.

Ultralife (NASDAQ:ULBI) last announced its quarterly earnings data on Thursday, November 2nd. The technology company reported $0.07 EPS for the quarter. Ultralife had a net margin of 6.61% and a return on equity of 7.83%. The company had revenue of $21.05 million during the quarter.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at

About Ultralife

Ultralife Corporation offers products and services ranging from power solutions to communications and electronics systems. The Company designs and manufactures power and communications systems, including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom engineered systems.

Insider Buying and Selling by Quarter for Ultralife (NASDAQ:ULBI)

Receive News & Ratings for Ultralife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultralife and related companies with's FREE daily email newsletter.